Tag: notice

BALA CYNWYD, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Performant Healthcare, Inc. (“Performant Healthcare” or the “Company”) (Nasdaq - PHLT) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Machinify. Under the terms of the transaction, Machinify will acquire all outstanding shares of Performant Healthcare for $7.75 per share in cash.

AB “Ignitis grupė” (hereinafter – the Group) informs that on the 1^st of August 2025 the Ministry of Finance of the Republic of Lithuania (hereinafter – the Ministry of Finance), which exercises the rights of the majority shareholder, announced the selection of three members from among civil servants to the Group’s Supervisory Board, in the areas of public policy and governance, regulatory, accounting and audit competences. Candidates may apply until the 21^st of August 2025 (inclusive).

AB “Ignitis grupė” (hereinafter – the Group) informs that on the 1^st of August 2025 the Ministry of Finance of the Republic of Lithuania (hereinafter – the Ministry of Finance), which exercises the rights of the majority shareholder, announced the selection of three members from among civil servants to the Group’s Supervisory Board, in the areas of public policy and governance, regulatory, accounting and audit competences. Candidates may apply until the 21^st of August 2025 (inclusive).

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months.